InsidersTradesSigma
Track the KURA ONCOLOGY INC stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €1.1bn. The latest transaction was filed on 21 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: BRIAN POWL. All data is accessible without an account.
Analysts rate KURA ONCOLOGY INC Strong Buy (bullish), based on 12 analysts. Average price target: US$32.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
Kura Oncology Inc is a biopharmaceutical company focused on developing treatments for cancer. It employs targeted approaches to address various types of malignant tumors.